Abstract | BACKGROUND: METHODS: We retrospectively analyzed the outcomes of 39 patients with PTCL received the two treatments between 1999 and 2010. RESULTS: The 3-year overall survival (OS) of 61.9% and 3-year progression free survival (PFS) of 35.7% were observed in the 39 patient. Twenty-one patients received Hyper-CVAD chemotherapy with 3-year OS of 46.2% and 3-year PFS of 27.9%. Eighteen patients received ASCT with 3-year OS of 70.3% and 3-year PFS of 44.2%. Further analysis revealed that patients with elevated lactate dehydrogenase, at least 2 international prognostic index (IPI) points, and extranodal involvement had a poorer outcome compared with the control group. CONCLUSION: These findings might suggest that Hyper-CVAD chemotherapy and ASCT could offer a durable survival benefit for patients with aggressive PTCL.
|
Authors | Yang Xu, Xiao-jin Wu, Ying Wang, Zheng-ming Jin, Ai-ning Sun, De-pei Wu |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 125
Issue 22
Pg. 4134-7
(Nov 2012)
ISSN: 2542-5641 [Electronic] China |
PMID | 23158157
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vincristine
- Dexamethasone
- Doxorubicin
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cyclophosphamide
(therapeutic use)
- Dexamethasone
(therapeutic use)
- Doxorubicin
(therapeutic use)
- Female
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Lymphoma, T-Cell, Peripheral
(drug therapy, therapy)
- Male
- Middle Aged
- Retrospective Studies
- Vincristine
(therapeutic use)
- Young Adult
|